Comment from PhRMA

Summary: PhRMA, a trade association representing biopharmaceutical research companies, supports the Commissioner’s National Priority Voucher (CNPV) Pilot Program as a way to accelerate patient access to therapies addressing national health priorities. They urge the FDA to formalize the program through notice-and-comment rulemaking to ensure transparency, predictability, and clear eligibility criteria while maintaining scientific rigor.